Key result
Streptokinase followed by heparin and warfarin showed no significant difference in 12-month mortality compared to anticoagulants alone in acute myocardial infarction (13.6% vs 17.0%).
Why the study?
Does streptokinase followed by heparin and warfarin reduce mortality in patients with acute myocardial infarction?
Population
747 patients with acute myocardial infarction
Comparison
Streptokinase followed by heparin and warfarin vs Anticoagulants only
Design
RCT
Follow-up
12 months
Loading...
No mortality benefit from adding streptokinase to anticoagulation in AMI; challenges expected thrombolytic benefit and informs subsequent antithrombotic trials.
Does streptokinase followed by heparin and warfarin reduce mortality in patients with acute myocardial infarction?
In this early trial, the addition of streptokinase to anticoagulation did not significantly reduce 12-month mortality in patients with acute myocardial infarction.
A 1977 study studied this question. Streptokinase followed by heparin and warfarin showed no significant difference in 12-month mortality compared to anticoagulants alone in acute myocardial infarction (13.6% vs 17.0%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: